QLESP Block for Pain Control in Robotic Partial Nephrectomy

Condition(s) studied

Investigational drug(s) / intervention(s)

ropivacaine (local infiltration): Ultrasound-guided QLESP block with 30 mL of 0.375% ropivacaine (15 mL injected between the erector spinae muscle and the transverse process at L2 level, followed by 15 mL injected between the quadratus lumborum and psoas major muscles) after induction of general anesthesia.

ropivacaine: Local wound infiltration with 30 mL of 0.375% ropivacaine at the port sites performed by the surgeon at the end of surgery.

Study summary

The goal of this clinical trial is to learn if an ultrasound-guided nerve block called QLESP works to reduce pain and the need for strong pain medicines after robotic kidney surgery in adults. The main questions it aims to answer are:

1. Does QLESP reduce the total amount of opioid pain medicine participants need in the first 48 hours after surgery?
2. Does QLESP lower pain scores and improve recovery quality after surgery? Researchers will compare participants who receive QLESP block to participants who receive the same numbing medicine injected only at the surgical wound sites.

Participants will:

1. Be randomly assigned to receive either QLESP or local wound injection before surgery.
2. Have a patient-controlled pain pump for 48 hours after surgery.
3. Complete pain scores and recovery quality questionnaires at 2, 6, 12, 24, 48, and 72 hours after surgery.
4. Be followed until hospital discharge.

Eligibility

Primary outcome measure(s)

• Cumulative Opioid Consumption at 48 Hours Postoperatively — From the end of surgery to 48 hours postoperatively.
  Cumulative opioid consumption measured at 48 hours after surgery

Trial sites (1)

More Huazhong University of Science and Technology trials in China

Other trials for the same condition